超越营养药品的极限:看待帕金森病和脆弱性
Martina Montanari1,2, Nicola Biagio Mercuri3,4, Giuseppina Martella2,5
1Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
International journal of molecular sciences
|January 11, 2025
概括
营养药物,来自食物的天然化合物,在对抗帕金森病 (PD) 和老年虚弱方面表现有前途. 它们的抗氧化特性可以减少氧化压力,提高老年人的治疗和性.
科学领域:
- 老年学是指老年学的学科.
- 神经科学是一个神经科学.
- 营养科学 营养科学
背景情况:
- 在全球范围内,老年人虚弱和帕金森病 (PD) 正在增加,这给健康带来了重大挑战.
- 这两种情况都有共同的特征,增加了老年人的脆弱性.
- 迫切需要创新的治疗策略来管理这些普遍的老年病症.
研究的目的:
- 审查营养保健品作为帕金森病和老年人虚弱的补充疗法的作用.
- 突出营养药在解决氧化应激,炎症和神经保护方面的潜在益处.
- 提出一个整体的管理方法,将营养药与其他干预措施整合起来.
主要方法:
- 对过去十年研究的文献综述.
- 对营养保健品作用机制的分析,重点关注抗氧化,抗炎和神经保护作用.
- 检查营养药与运动,药物治疗和生活方式调整的协同作用潜力.
主要成果:
- 营养药,特别是富含抗氧化剂的营养药,在治疗PD和老年人虚弱方面表现出显著的潜力.
- 抗氧化营养药可以减轻PD中多巴诱导的氧化损伤,改善治疗的可持续性.
- 营养药可以增强体育活动的益处,改善老年人的肌肉功能,认知健康和性.
结论:
- 营养药物为帕金森病和老年人虚弱提供了一个有前途的补充治疗策略.
- 将营养药与运动,药物治疗和生活方式改变相结合的整体方法可以改变与年龄有关的疾病的管理.
- 营养保健品的整合有可能延长寿命并改善老年人的生活质量.
相关概念视频
Parkinson's Disease: Treatment
215
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
215
Parkinson's Disease: Overview
472
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
472
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
Role of Vitamins in Maintaining Bone Health
3.1K
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
3.1K
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444


